JP2012519694A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012519694A5 JP2012519694A5 JP2011553071A JP2011553071A JP2012519694A5 JP 2012519694 A5 JP2012519694 A5 JP 2012519694A5 JP 2011553071 A JP2011553071 A JP 2011553071A JP 2011553071 A JP2011553071 A JP 2011553071A JP 2012519694 A5 JP2012519694 A5 JP 2012519694A5
- Authority
- JP
- Japan
- Prior art keywords
- aqueous solution
- peg
- composition
- item
- solution according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007864 aqueous solution Substances 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 30
- 239000013543 active substance Substances 0.000 claims description 18
- 229920001223 polyethylene glycol Polymers 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 239000008118 PEG 6000 Substances 0.000 claims description 10
- 229920002538 Polyethylene Glycol 20000 Polymers 0.000 claims description 10
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 10
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 6
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 6
- 206010029113 Neovascularisation Diseases 0.000 claims description 5
- 208000022873 Ocular disease Diseases 0.000 claims description 5
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 4
- MPVGZUGXCQEXTM-UHFFFAOYSA-N linifanib Chemical group CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 claims description 4
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims description 4
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims description 4
- 230000008728 vascular permeability Effects 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 208000008069 Geographic Atrophy Diseases 0.000 claims description 2
- 208000001344 Macular Edema Diseases 0.000 claims description 2
- 206010025415 Macular oedema Diseases 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 230000002137 anti-vascular effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 201000010230 macular retinal edema Diseases 0.000 claims description 2
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 9
- 230000033115 angiogenesis Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15692209P | 2009-03-03 | 2009-03-03 | |
| US61/156,922 | 2009-03-03 | ||
| PCT/US2010/026033 WO2010101992A1 (en) | 2009-03-03 | 2010-03-03 | Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012519694A JP2012519694A (ja) | 2012-08-30 |
| JP2012519694A5 true JP2012519694A5 (cg-RX-API-DMAC7.html) | 2013-03-07 |
| JP5583146B2 JP5583146B2 (ja) | 2014-09-03 |
Family
ID=42678800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011553071A Expired - Fee Related JP5583146B2 (ja) | 2009-03-03 | 2010-03-03 | レセプターチロシンキナーゼ阻害（ＲＴＫｉ）化合物の眼への送達のための薬学的組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20100227905A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2403335B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5583146B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20160135372A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102340991B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010221369B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI1012302A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2753690A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2508290T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2011008731A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010101992A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201105505B (cg-RX-API-DMAC7.html) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7973142B2 (en) | 2006-04-07 | 2011-07-05 | Warner Chilcott Company | Antibodies that bind human protein tyrosine phosphatase beta (HPTPβ) |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| MX2011007420A (es) | 2009-07-06 | 2011-12-14 | Akebia Therapeutics Inc | Compuestos, composiciones y metodos para prevenir la metastasis de las celulas cancerigenas. |
| CA2791278C (en) | 2010-02-25 | 2015-11-24 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
| AU2011282252B2 (en) * | 2010-07-21 | 2014-08-21 | Alcon Research, Ltd. | Pharmaceutical composition with enhanced solubility characteristics |
| US10307372B2 (en) | 2010-09-10 | 2019-06-04 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
| US9327037B2 (en) | 2011-02-08 | 2016-05-03 | The Johns Hopkins University | Mucus penetrating gene carriers |
| US20140160236A1 (en) * | 2011-07-29 | 2014-06-12 | The Regents Of The University Of California | Lensfree holographic microscopy using wetting films |
| EP3505182A1 (en) | 2011-10-13 | 2019-07-03 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
| CA2863632C (en) | 2012-01-19 | 2017-07-11 | The Johns Hopkins University | Nanoparticle formulations with enhanced mucosal penetration |
| EP2825206A1 (en) | 2012-03-16 | 2015-01-21 | The Johns Hopkins University | Controlled release formulations for the delivery of hif-1 inhibitors |
| US10159743B2 (en) | 2012-03-16 | 2018-12-25 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| HK1208162A1 (en) | 2012-05-03 | 2016-02-26 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| EP3808339B1 (en) | 2012-05-03 | 2025-11-12 | Alcon Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| US9889208B2 (en) | 2012-05-04 | 2018-02-13 | The Johns Hopkins University | Lipid-based drug carriers for rapid penetration through mucus linings |
| WO2014124006A1 (en) | 2013-02-05 | 2014-08-14 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| MX368142B (es) * | 2013-04-30 | 2019-09-20 | Intas Pharmaceuticals Ltd | Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab. |
| WO2015127389A1 (en) | 2014-02-23 | 2015-08-27 | The Johns Hopkins University | Hypotonic enema formulations and methods of use |
| CN106456614A (zh) | 2014-03-14 | 2017-02-22 | 爱尔皮奥治疗有限公司 | HPTP‑β抑制剂 |
| RU2729731C2 (ru) | 2014-12-15 | 2020-08-11 | Зе Джонс Хопкинс Юниверсити | Составы на основе сунитиниба и способы их применения для лечения глазных заболеваний |
| KR20240126072A (ko) | 2015-01-27 | 2024-08-20 | 더 존스 홉킨스 유니버시티 | 점막표면에서 활성제의 향상된 수송을 위한 저장성 하이드로겔 제제 |
| EP4414032A3 (en) | 2015-09-23 | 2024-11-06 | EyePoint Pharmaceuticals, Inc. | Methods of treating intraocular pressure with activators of tie-2 |
| EP3373978A4 (en) | 2015-11-12 | 2019-06-26 | Graybug Vision, Inc. | AGGREGATION OF MICROPARTICLES FOR THERAPY |
| CA3056923A1 (en) | 2017-03-23 | 2018-09-27 | Graybug Vision, Inc. | Drugs and compositions for the treatment of ocular disorders |
| WO2018209155A1 (en) | 2017-05-10 | 2018-11-15 | Graybug Vision, Inc. | Extended release microparticles and suspensions thereof for medical therapy |
| WO2020210805A1 (en) | 2019-04-11 | 2020-10-15 | The Johns Hopkins University | Nanoparticles for drug delivery to brain |
| AU2020264969B2 (en) | 2019-04-29 | 2025-06-05 | EyePoint, Inc. | Tie-2 activators targeting the schlemm's canal |
| EP4065131B1 (en) * | 2019-11-28 | 2024-09-18 | Caprika Srl | Rectal-use composition for the treatment of constipation |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| HU220864B1 (en) * | 1993-04-16 | 2002-06-29 | Wakamoto Pharma Co Ltd | Reversible, thermally gelling water-base medicinal compositions |
| CN1126545C (zh) * | 1996-05-07 | 2003-11-05 | 东丽株式会社 | 眼科用制剂 |
| SI1638941T1 (sl) * | 2003-05-22 | 2010-11-30 | Abbott Lab | Inhibitorji indazol benzizoksazol in benzizotiazol kinaze |
| TW200640443A (en) * | 2005-02-23 | 2006-12-01 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors |
| CN101006988A (zh) * | 2005-09-26 | 2007-08-01 | 刘凤鸣 | 葛根素的缓释制剂 |
| EP1965762A1 (en) * | 2005-12-23 | 2008-09-10 | Alcon, Inc. | Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
| US20070149593A1 (en) * | 2005-12-23 | 2007-06-28 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| BRPI0721885A2 (pt) * | 2007-07-20 | 2014-02-25 | Alcon Inc | Formulação farmacêutica para distribuição de compostos inibidores de receptores de tirosina quinase (rtki) para os olhos |
-
2010
- 2010-03-03 KR KR1020167032103A patent/KR20160135372A/ko not_active Abandoned
- 2010-03-03 US US12/716,663 patent/US20100227905A1/en not_active Abandoned
- 2010-03-03 BR BRPI1012302A patent/BRPI1012302A2/pt not_active IP Right Cessation
- 2010-03-03 WO PCT/US2010/026033 patent/WO2010101992A1/en not_active Ceased
- 2010-03-03 KR KR1020117023001A patent/KR20110130454A/ko not_active Ceased
- 2010-03-03 JP JP2011553071A patent/JP5583146B2/ja not_active Expired - Fee Related
- 2010-03-03 MX MX2011008731A patent/MX2011008731A/es active IP Right Grant
- 2010-03-03 CN CN201080010150.0A patent/CN102340991B/zh not_active Expired - Fee Related
- 2010-03-03 AU AU2010221369A patent/AU2010221369B2/en not_active Ceased
- 2010-03-03 ES ES10749258.9T patent/ES2508290T3/es active Active
- 2010-03-03 EP EP10749258.9A patent/EP2403335B1/en not_active Not-in-force
- 2010-03-03 CA CA2753690A patent/CA2753690A1/en not_active Abandoned
-
2011
- 2011-07-26 ZA ZA2011/05505A patent/ZA201105505B/en unknown
-
2013
- 2013-01-25 US US13/749,887 patent/US20130137741A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012519694A5 (cg-RX-API-DMAC7.html) | ||
| JP2012519692A5 (cg-RX-API-DMAC7.html) | ||
| US11951103B2 (en) | Pharmaceutical composition | |
| JP5739908B2 (ja) | 血管形成関連の眼疾患の処置のための組成物および方法 | |
| JP6677827B2 (ja) | 眼科用医薬組成物 | |
| JP6641062B2 (ja) | テコビリマットの経口用医薬組成物及びその調製法 | |
| TW202216119A (zh) | 眼用活性醫藥成分輸送的固態環糊精複合物製備 | |
| JP2020524163A (ja) | ペプチド組成物および関連方法 | |
| JP2025098194A (ja) | 薬剤を含む水性組成物のｐＨを安定化させるための方法 | |
| JP5934229B2 (ja) | 眼血管疾患の処置のための投与計画 | |
| JP5113323B2 (ja) | ジクロフェナクナトリウムとβ−シクロデキストリンとを有する注入可能薬学組成物 | |
| US20180009758A1 (en) | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use | |
| RU2017112930A (ru) | Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза | |
| WO2012105610A1 (ja) | 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬 | |
| US20170342033A1 (en) | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use | |
| JP6931257B2 (ja) | レバミピドを含有する新規ドライアイ治療用点眼組成物及びその可溶化及び安定化方法 | |
| CN101687042A (zh) | 用于递送作为受体酪氨酸激酶抑制剂(RTKi)的化合物至眼部的药物制剂 | |
| US20160376239A1 (en) | N-Acylalkyl Prodrugs of Multi-Tyrosine Kinase Inhibitors and Methods of Use | |
| KR20220025775A (ko) | 디쿠아포솔을 포함하는 점안 조성물 | |
| AU2019226830A1 (en) | Eye drops in form of solution comprising benzopyran derivative or pharmaceutically acceptable salt thereof | |
| US10464902B1 (en) | Multi-tyrosine kinase inhibitors derivatives and methods of use | |
| US11623917B2 (en) | Multi-tyrosine kinase inhibitors derivatives and methods of use | |
| CA2932313A1 (en) | Dry enema product | |
| US20170020856A1 (en) | N-Acylalkyl Prodrugs of Multi-Tyrosine Kinase Inhibitors and Methods of Use | |
| JP2019163227A (ja) | 医薬組成物 |